* Advair Diskus achieves primary endpoint in LABA safety study of children aged 4-11 years with asthma Source text for Eikon: Further company coverage: (Reporting by UK bureau)
The post BRIEF-GSK’s Advair achieves primary endpoint in safety study of children appeared first on NASDAQ.